



Department of Obstetrics and Gynaecology  
Queen Mary Hospital  
The University of Hong Kong



# Gynaecological Oncology

Annual Report  
2019



# Gynaecological Oncology

Department of Obstetrics and Gynaecology  
Queen Mary Hospital  
The University of Hong Kong

Annual Report 2019



**HKU  
Med**

LKS Faculty of Medicine  
Department of Obstetrics  
& Gynaecology  
香港大學婦產科學系

## Message from Division Head

The gynaecological oncology division of the Department of Obstetrics and Gynaecology, the University of Hong Kong, has been providing training and service in gynaecological oncology for over 50 years. Our unit is a tertiary referral center for both the private and public sectors in Hong Kong. We also accept referrals from the hospitals in Macau. With collaboration with other departments, our scope of services includes colposcopy, chemotherapy, radiotherapy, surgery and palliative care.

Our unit is a recognized training center for gynaecological oncology by the Hong Kong College of Obstetricians and Gynaecologists (HKCOG) and the Royal College of Obstetricians and Gynaecologists (RCOG). In 2019, we had Dr. Victoria Chai with us for her third year of subspecialist training in gynaecological oncology. Apart from training subspecialist fellow, we also provide gynaecological oncology training for basic and higher specialist trainees in Obstetrics and Gynaecology, not only from our unit but also other hospitals in Hong Kong.

In November 2019, we invited Dr John Latimer, a gynaecological oncologist from the Cambridge University Hospitals in the United Kingdom as the Licentiate Examiner.

In addition to clinical service and research activities, our division was also active in promoting women's health in Hong Kong by giving public talks and presentations in the Family Planning Association, radio and TV programmes.

I would like to take this opportunity to thank our team members and our collaborators for their contribution.



H.Y.S. Ngan

Tso Yin-Kai Professor

Head of Department

## **Table of contents**

I	Staff List	4
II	Laboratory	7
III	Inpatient & Outpatient Services	9
IV	Team Activities	10
V	Outpatient Statistics	11
VI	Colposcopy Services	12
VII	Cervical Malignancies	14
VIII	Uterine Malignancies	15
IX	Ovarian Malignancies	17
X	Gestational Trophoblastic Neoplasia	19
XI	Vulval, Vaginal and Fallopian Tube Cancers	20
XII	Multiple Primary Malignancies	21
XIII	Operations for Malignant/Pre-malignant Diseases	22
XIV	Chemotherapy	24
XV	Publications and Abstracts	26

# Staff List

## **Gynaecological Oncologists**

Professor Ngan Yuen Sheung Hextan, Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Chan Kar Loen Karen, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Tse Ka Yu, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Chu Man Yee Mandy, Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital

Dr. Ngu Siew Fei, Assistant Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

## ***Subspecialist Trainee***

Dr. Chai Yu Ka Victoria, Associate Consultant, Department of Obstetrics and Gynaecology, United Christian Hospital

## ***Specialist Gynaecologists***

Dr. Chan Man Ka Diana, Resident Specialist, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jan – 30 Jun 2019)

Dr. Kwok Shuk Tak Gladys, Resident Specialist, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jul – 31 Dec 2019)

## ***Residents***

Dr. Ng Shu Man Carmen, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jan – 14 Feb 2019)

Dr. Chan Hey Yin Aaron, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Apr – 15 May 2019)

Dr. Wai Kar On Joan, Lecturer, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Apr – 30 Jun 2019)

Dr. Ng Wai Yan Vivian, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jul – 30 Sep 2019)

### **Clinical Oncologists**

Dr. Luk Mei Yee, Chief of Service, Department of Clinical Oncology, Queen Mary Hospital

Dr. Siu Wai Kwan Steven, Consultant, Department of Clinical Oncology, Queen Mary Hospital

### **Pathologists**

Professor Ng Oi Lin Irene, Head of Department, Department of Pathology, University of Hong Kong

Professor Cheung Nga Yin Annie, Professor, Department of Pathology, University of Hong Kong

Dr. Ip Pun Ching Philip, Associate Professor, Department of Pathology, Queen Mary Hospital

### **Consultant Colorectal Surgeon**

Professor Law Wai Lun, Professor, Department of Surgery, Queen Mary Hospital

Dr. Oswens Siu-Hung Lo, Consultant, Department of Surgery, Queen Mary Hospital

### **Consultant Urologist**

Dr. Tsu Hok Leung James, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

### **Consultant Plastic Surgeon**

Dr. Chow Ling Yu Velda, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

### **Consultant Medical Oncologist**

Professor Kwong Yok Lam, Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, University of Hong Kong

### **Consultant Radiologist**

Dr. Lam Poy Wing Tina, Chief of Service, Department of Radiology, Queen Mary Hospital

Dr. Lee Yuen Phin Elaine, Assistant Professor, Department of Radiology, University of Hong Kong

### **Consultant Anaesthesiologist**

Dr. Chee Yee Eot, Chief of Service, Department of Anaesthesiology, Queen Mary Hospital

### **Consultant Clinical Psychologist**

Dr. Lina Wu, Senior Clinical Psychologist, Department of Psychiatry, Queen Mary Hospital

### **Medical Social Workers**

Ms Au Suk Cheung Helen, Social Welfare Department

### **Nurse Specialist in Stoma Care**

Ms. Chan Lai Hung, Nursing Officer, Queen Mary Hospital

### **Cluster Rehabilitative Palliative Care Team**

Dr. Chan Kwok Ying, Consultant, Palliative Medicine Unit, Grantham Hospital

Dr. Li Cho Wing Bryan, Associate Consultant, Palliative Medicine Unit, Grantham Hospital

Ms. Chiu Ho Yan, Registered Nurse, Grantham Hospital

### **Clinical Research Team**

Ms Lau Suk Kwan Lesley, Research Co-ordinator

Dr. Wei Na Tina, Research Co-ordinator

Ms. Yu Ping Ching Amy, Research Nurse (part-time)

# Laboratory

## Staff

Dr. Chan Wai David, Assistant Professor  
Dr. Chan Wai Sun, Post-doctoral Fellow  
Dr. Chan Yau Sang, Post-doctoral Fellow  
Dr. Leung Ho Yin Thomas, Post-doctoral Fellow  
Dr. Yung Ming Ho Mingo, Post-doctoral Fellow  
Dr. Liu Si Stephanie, Research Officer  
Dr. Siu Kwan Yee Michelle, Research Officer  
Mr. Chan Chan Keung Milton, Technician  
Mr. Chen Fu Shun, Senior Research Assistant  
Dr. Chan Kin Tak, Research Assistant  
Ms. He Fang Fang, Research Assistant  
Miss Ling Sho Sarah, Research Assistant  
Miss Lui Tsz Yiu Esther, Research Assistant  
Miss Tang Wai Man Hermit, Research Assistant

## Services

Hormonal assay and assays for tumour markers

## Research tools

HPV detection and genotyping

ELISA

Immunohistochemistry

In situ hybridization assay

DNA, RNA and protein extractions

Conventional PCR and RT-PCR

Quantitative PCR

Quantitative RT-PCR

RNA protection assay

Western blot

DNA methylation analysis

DNA sequencing

Microarray analysis

Cell line and culture

Transfection study

RNAi study

Apoptotic assay

Clonogenic assay

Cytotoxicity assay

Cell proliferation assay

DNA copy number variation analysis

Protein co-immunoprecipitation

Gene cloning

In vivo animal study

Laser-captured microdissection



Hypoxia chamber  
Flow cytometry  
Yeast two hybrid  
Fluorescent microscopy  
Fluorescent stereomicroscopy  
Li-Cor Odyssey CLx near-infrared fluorescence imaging system  
Gel documentation system  
Microplate reader  
SpectraMax L Microplate Reader

3D organoids assay  
Omics analysis  
Omental conditioned medium model  
Ex vivo omental-tumor model

# **Inpatient Services**

## **Gynaecological oncology ward**

22 beds in the open ward  
2 private beds  
3 day beds

## **Ward Manager**

Ms. Hui Fung Ping, Susanna

## **Operating Theatre**

2 Full-day lists per week

## **Operating Theatre Manager**

Ms. Sylvia Wong

# **Outpatient Services**

Colposcopy Clinic	4 sessions per week
Chemotherapy Clinic	1 session per week
Cancer follow-up Clinic	1 session per week
Trophoblastic Clinic	1 session per week
Day Chemotherapy	5 days per week
Patient Group Meeting	1 session per 3 weeks
Palliative Medicine Clinic	1 session per week
Pre-admission Clinic	1 session per week

## **Clinic In-charge**

Ms. Chung Suk Man, Advanced Practice Nurse, S5, Queen Mary Hospital

## Team Activities

Grand Round (Led by Prof. Hextan Ngan)	1 per week
Discussion of New Cases and Treatment (Led by Prof. Hextan Ngan)	1 per week
Radiology Meeting (Led by Prof. Hextan Ngan and Dr. Elaine Lee)	1 per week
Chemotherapy Meeting (Led by Prof. Hextan Ngan)	1 per week
Morbidities and Mortality Meeting (Led by Prof. Hextan Ngan)	1 per week
Pre-operative Round (Led by Prof. Hextan Ngan)	1 per week
Tumour Board Meeting/Pathology Review (Led by Prof. Hextan Ngan and Prof. Annie Cheung)	1 per week
Laboratory Research Meeting (Led by Prof. Hextan Ngan)	1 per month
Clinical Research Meeting (Led by Prof. Hextan Ngan)	1 per month

# Outpatient Statistics

<b><i>Oncology Clinics Attendances</i></b>	2015	2016	2017	2018	<b>2019</b>
Cancer Follow-up Clinic	4249	4010	4183	4322	<b>4207</b>
Trophoblastic Clinic	766	907	856	726	<b>667</b>
Chemotherapy Clinic	2082	1894	1758	2044	<b>2219</b>
Preadmission Clinic	-	-	-	95	<b>174</b>
Research Clinic					<b>15</b>

## ***Patient Group Meeting***

### **Oncology patients support group which was led by:**

Ms. Susanna Hui (Ward Manager)  
Ms. Tang Lai Chun (Advanced Practice Nurse)  
Ms. Cheng Sze Ki (Registered Nurse)  
Ms Tam Siu Man (Registered Nurse)

### **Stoma patients support group which was led by:**

Ms. Susanna Hui (Ward Manager)  
Ms. Chan Lai Hung (Nursing Officer)  
Ms Tam Siu Man (Registered Nurse)

### **Oncology patient support group:**

Total no. of sessions: 13

Total no. of attendance: 100 patients + 46 relatives = 146

### **Stoma patient support group:**

Total no. of sessions: 3

Total no. of attendance: 14 patients + 4 relative = 18

### **Annual patient group party:**

Attendance: 77 patients + 17 relatives = 94

# Colposcopy Services

## *Colposcopy Clinics*

### **Queen Mary Hospital**

4 sessions - Monday afternoon, Tuesday morning, Thursday and Friday afternoon

## *Cervical Smear Clinics (run by nurses)*

### **Queen Mary Hospital**

3 session - Monday afternoon, Tuesday morning and Thursday afternoon

### **WDTC**

4 sessions - Monday and Tuesday (full day)

## **Statistics**

New Cases	682
Follow-up	1378


<b>Diagnosis (based on worst histology)</b>	<b>Cervix</b>	<b>Vagina</b>	<b>Vulva</b>
Normal	100	24	
Inflammation	47		1
Warts/HPV	130	4	1
Low grade squamous intraepithelial lesion	207	18	
High grade squamous intraepithelial lesion	97	7	
Microinvasive carcinoma			
Squamous cell carcinoma	4		
Adenocarcinoma	3		
Adenocarcinoma in-situ	1		
No histology	94	14	
Unsatisfactory for assessment	9		
Others			
Atrophy	2		
Atypical cells	2		
Endocervical polyp	2		
Metastatic adenocarcinoma	1		
Paget's disease			1
Recurrence of cervical cancer		1	

**Procedures**

Cone biopsy	2
Cryotherapy	1
Large loop excision of transformation zone	103
Under local anaesthesia	95
Under general / spinal anaesthesia	9


# Cervical Malignancies

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Total Number of New cases	87	98	62	83	84	82	87	101	73	84	91
Stage I	49	36	26	36	42	42	43	36	36	33	27
Stage II	17	35	27	22	21	19	17	26	18	24	23
Stage III	13	11	4	15	16	14	12	14	11	11	18
Stage IV	4	5	3	5	3	2	6	8	3	9	14
Unstaged	2	3	1	1	1	3	0	5	2	4	1
Recurrence	2	8	1	4	1	2	9	12	3	3	8



## 2019 New Case


Age	Case Number
≤ 30	4
31-40	18
41-50	18
51-60	17
61-70	21
71-80	8
> 80	5
<b>Total</b>	<b>91</b>



# Uterine Malignancies


## Carcinoma of Endometrium

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Total Number of New Cases	81	100	78	110	121	146	115	134	128	147	<b>162</b>
Stage I	43	64	45	64	70	83	69	88	81	88	<b>106</b>
Stage II	7	10	5	10	8	16	10	10	11	14	<b>9</b>
Stage III	10	15	16	23	25	26	18	23	24	26	<b>24</b>
Stage IV	4	4	5	4	5	12	7	9	6	13	<b>12</b>
Unstaged	12	6	4	7	10	8	7	2	3	5	<b>2</b>
Recurrence	5	1	3	2	3	1	4	2	3	1	<b>9</b>



## 2019 New Case

Age	
≤ 30	3
31-40	10
41-50	30
51-60	61
61-70	46
71-80	9
> 80	3
Total	162






## Other Uterine Malignancies

	2014	2015	2016	2017	2018	2019
Endometrial stromal sarcoma	3	3	5	3	8	<b>3</b>
Leiomyosarcoma	6	6	5	14	7	<b>9</b>
Malignant mixed mullerian tumor (MMMT)	14	5	8	11	8	<b>8</b>
Adenosarcoma	2	0	0	1	0	<b>0</b>
Chondrosarcoma	0	0	0	1	0	<b>0</b>
Rabdomyosarcoma	0	0	0	1	0	<b>0</b>
Smooth muscle tumour of undetermined malignant potential (STUMP)	1	1	3	0	1	<b>3</b>
Dedifferentiated endometrial carcinoma	0	0	0	1	0	<b>0</b>
Undifferentiated endometrial sarcoma	0	2	0	0	0	<b>1</b>
Uterine tumour resembling ovarian sex cord tumour	0	0	0	1	0	<b>0</b>
Uterine small cell carcinoma	0	0	1	0	1	<b>0</b>
Undifferentiated carcinoma	0	0	1	1	4	<b>0</b>

# Ovarian Malignancies


## Epithelial Ovarian Cancer

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Total Number of New cases	47	69	55	61	64	78	76	76	66	79	<b>95</b>
Stage I	21	21	22	26	30	25	22	32	14	27	<b>40</b>
Stage II	3	4	6	9	7	7	5	4	11	2	<b>8</b>
Stage III	11	13	21	16	16	32	33	16	22	14	<b>25</b>
Stage IV	4	15	6	4	10	9	10	13	12	14	<b>15</b>
Unstaged	0	7	0	2	1	1	1	2	1	1	<b>0</b>
Recurrence	8	9	0	4	0	4	5	9	6	21	<b>7</b>



## 2019 New Case

Age	
≤ 30	6
31-40	10
41-50	25
51-60	30
61-70	16
71-80	7
> 80	1
Total	95



## Ovarian Tumour of Low Malignant Potential

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Number of new cases	15	13	8	19	19	19	18	13	22	12	<b>13</b>
Stage I	12	11	7	15	14	15	16	6	19	10	<b>12</b>
Stage II	0	0	0	0	2	1	0	1	2	0	<b>0</b>
Stage III	1	1	0	2	2	2	2	1	0	1	<b>1</b>
Unstaged	0	0	0	0	1	0	0	0	0	0	<b>0</b>
Recurrence	1	1	1	2	0	1	0	4	1	0	<b>0</b>

## Germ Cell Tumour

3 patients had stage 1c immature teratoma.

1 patient had stage at least 1a yolk sac tumour.

1 patient had stage 4 yolk sac tumour.

1 patient had stage 1a dysgerminoma

1 patient had stage at least 1c1 dysgerminoma

## Sex Cord-Stromal Tumour

2 patients had stage 1a granulosa cell tumour.

1 patient had unstaged granulosa cell tumour.

1 patient had stage 2a granulosa cell tumour.

3 patients had recurrent granulosa cell tumour.

## Other Ovarian Malignancies

1 patient had stage 1c2 mesonephric-like carcinoma.


1 patient had recurrent carcinosarcoma.

## Primary Peritoneal Carcinoma

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Total	10	19	3	13	10	10	9	15	9	11	<b>16</b>
Stage II			0	2	0	0	0	1	0	0	<b>0</b>
Stage III			1	5	7	4	7	9	1	6	<b>8</b>
Stage IV			2	5	3	4	1	4	3	4	<b>7</b>
Unstaged			0	1	0	1	0	1	4	1	<b>1</b>
Recurrence			0	0	0	1	1	0	1	0	<b>0</b>


# Gestational Trophoblastic Neoplasia

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Number of New cases	9	15	10	21	16	17	14	12	10	12	10
Stage I	6	10	9	18	12	10	8	8	8	9	6
Stage II	1	1	1	0	0	1	0	0	0	1	0
Stage III	2	1	0	2	2	5	2	2	2	2	2
Stage IV	0	1	0	1	2	0	1	1	0	0	1
Unstaged	0	0	0	0	0	0	0	0	0	0	1
Recurrence	0	2	0	0	0	1	1	1	0	0	0



## 2019 New case

Age	
≤ 30	2
31-40	3
41-50	4
> 50	1
Total	10



# Vulval, Vaginal and Fallopian Tube Cancers

## Vulval Cancer

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	<b>2019</b>
Number of New Cases	8	11	5	8	7	9	6	6	9	12	<b>9</b>
Stage I	1	5	0	2	4	4	0	3	6	2	<b>2</b>
Stage II	2	0	0	1	0	0	1	0	0	4	<b>0</b>
Stage III	2	2	2	1	1	3	1	1	3	1	<b>2</b>
Stage IV	2	1	1	2	1	0	1	0	0	1	<b>2</b>
Unstaged	1	2	2	1	0	1	1	1	0	2	<b>2</b>
Recurrence	0	1	0	1	1	1	2	1	0	2	<b>1</b>

## Vaginal Cancer

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	<b>2019</b>
Number of New Cases	4	0	5	8	3	3	5	7	5	5	<b>4</b>
Stage I	0	0	0	2	0	1	0	0	0	0	<b>0</b>
Stage II	2	0	4	1	1	1	4	5	1	3	<b>2</b>
Stage III	1	0	1	1	0	0	0	0	1	2	<b>0</b>
Stage IV	0	0	0	2	2	0	1	1	2	0	<b>0</b>
Unstaged	1	0	0	1	0	0	0	0	0	0	<b>1</b>
Recurrence	0	0	0	1	0	1	0	1	1	0	<b>1</b>

## Fallopian Tube Cancer

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	<b>2019</b>
Number of New Cases	3	0	0	1	0	3	2	5	4	2	<b>1</b>
Stage I	1	0	0	1	0	0	0	0	1	0	<b>0</b>
Stage II	0	0	0	0	0	0	0	1	2	0	<b>0</b>
Stage III	1	0	0	0	0	1	0	2	0	1	<b>1</b>
Stage IV	1	0	0	0	0	2	2	1	1	0	<b>0</b>
Unstaged	0	0	0	0	0	0	0	0	0	0	<b>0</b>
Recurrence	0	0	0	0	0	0	0	1	0	1	<b>0</b>

# Multiple Primary Malignancies

2019 Number  
17

Primary	Stage	Primary	Stage	Number
Ca Corpus	I	Ca Ovary	I	7
	I	Granulosa Cell Tumour	I	1
	I	Ca Fallopian Tube	II	1
	I	Ca Fallopian Tube	III	1
	I	Ca Lung	III	1
	II	Ca Fallopian Tube	III	1
	III	Ca Thyroid	IV	1
	I	Ca Ureter	III	1

## Triple primary case

2 patients had Ca Corpus stage I and bilateral Ca Ovary stage I.

1 patient had Ca Corpus stage II and bilateral Ca Ovary stage I.

## Operation for Malignant/Pre-malignant Diseases

	<b>Number of procedures</b>
Laparotomy (all cases with open abdominal surgery)	124
Radical hysterectomy +/- unilateral / bilateral salpingo-oophorectomy (U/BSO)	4
Laparoscopic radical hysterectomy +/- U/BSO	0
Laparoscopic radical hysterectomy +/- U/BSO (Da Vinci)	4
Modified radical hysterectomy +/- U/BSO	6
Laparoscopic modified radical hysterectomy +/- U/BSO (Da Vinci)	4
Total abdominal hysterectomy +/- U/BSO	100
Total laparoscopic hysterectomy +/- U/BSO	49
Total laparoscopic hysterectomy +/- U/BSO (Da Vinci)	24
Laparoscopic radical trachelectomy (Da Vinci)	1
Pelvic lymphadenectomy (one side)	89
Laparoscopic pelvic lymphadenectomy (one side)	21
Laparoscopic pelvic lymphadenectomy (one side) (Da Vinci)	66
Paraaortic lymphadenectomy	41
Laparoscopic paraaortic lymphadenectomy	2
Laparoscopic paraaortic lymphadenectomy (Da Vinci)	18
Omentectomy	71
Laparoscopic omentectomy	6
Laparoscopic omentectomy (Da Vinci)	8
Adhesiolysis	21
Laparoscopic adhesiolysis	8
Laparoscopic adhesiolysis (Da Vinci)	4
BSO / USO / ovarian cystectomy	8
Laparoscopic BSO / USO / ovarian cystectomy	9

Appendicectomy	12
Laparoscopic appendicectomy	1
Laparoscopic appendicectomy (Da Vinci)	1
Debulking surgery	33
HIPEC	4
Bowel resection and re-anastomosis	6
Colostomy / ileostomy	4
Closure of stoma	3
Repair of bowel	5
Repair of bladder	0
Repair of vessels	0
Repair of vagina / perineum	4
Vault stripping / vaginectomy	8
Wide local excision of vulva	2
Radical vulvectomy	6
Groin node dissection (one side)	15
Cone biopsy	1
Large loop excision of transformation zone	2
Brachytherapy	40
Removal or insertion of central line insertion	2
Diagnostic hysteroscopy	8
Hysteroscopic polypectomy	2
Suction evacuation	1
Laparoscopic biopsy	7
Diagnostic laparoscopy	7
Examination under anaesthesia	1
Cystoscopy	1



# Chemotherapy

Total number of patients receiving in-patient chemotherapy: 241

Total number of patients receiving out-patient chemotherapy: 258

Total number of patients receiving oral chemotherapy: 3

Total number of patients receiving PARP inhibitors: 25

Chemotherapy Regimen	Number of courses	
	In patient	Outpatient
Adriamycin	8	12
Adriamycin/Cisplatin	1	4
Avelumab/Axitinib (clinical trial)	9	0
BEP (bleomycin, etoposide, cisplatin)	5	11
Bevacizumab	7	42
Carboplatin	19	38
Carboplatin/Etoposide	1	6
Carboplatin/Gemcitabine	8	9
Carboplatin/Gemcitabine/Bevacizumab	1	5
Carboplatin/Iriontecan	2	0
Carboplatin/Liposomal doxorubicin	9	31
Carboplatin/Paclitaxel	348	580
Carboplatin/Paclitaxel (weekly)	1	0
Carboplatin (weekly)/Paclitaxel (weekly)	2	0
Carboplatin/Paclitaxel/Bevacizumab	19	17
Cisplatin	32	89
Cisplatin/Etoposide	1	0
Cisplatin/Gemcitabine	3	2
Cisplatin/Gemcitabine/Bevacizumab	1	0
Cisplatin/Paclitaxel	14	4
Cisplatin/Paclitaxel/Bevacizumab	7	0
Cyclophosphamide (oral)	0	9
EMA-CO (etoposide, methotrexate and actinomycin D/ cyclophosphamide and vincristine)	1	0
Etoposide (oral)	0	1
Gemcitabine	23	77

Gemcitabine/Taxotere	0	3
Ifosfamide	3	0
Liposomal doxorubicin	35	35
Liposomal doxorubicin/Bevacizumab	1	20
Methotrexate (intravenous)	26	0
Methotrexate/Actinomycin D	19	0
Niraparib	0	57
Olaparib	0	118
Paclitaxel	6	14
Pembrolizumab	4	0
Topotecan	34	56
Topotecan/Bevacizumab	1	10
XELOX (capecitabine and oxaliplatin)	2	3
<b>Total number of courses of chemotherapy</b>	<b>653</b>	<b>1253</b>

# Publications

## Scholarly books, monographs and chapters

Ngu S.F. and Chan K.K.L., Genital Tract Cancers, In: Department of Obstetrics and Gynaecology, The University of Hong Kong, *Practical Obstetrics and Gynaecology*. Hong Kong, Department of Obstetrics and Gynaecology, HKU, 2019, 247-263.

## Journal publications

An H., Chiu W.H.K., Tse K.Y., Ngan H.Y.S., Khong P.L. and Lee E.Y.P., The Value of Contrast-Enhanced CT in the Detection of Residual Disease After Neo-Adjuvant Chemotherapy in Ovarian Cancer, *Academic Radiology*. 2019, 27, 951-957.

Chen R., Yung M.H., Xuan Y., Zhan S., Leung L.L., Liang R., Leung T.H.Y., Yang H.J., Xu D., Sharma R., Chan K.K.L., Ngu S.F., Ngan H.Y.S. and Chan D.W., Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells, *Communications Biology*. 2019, 2.

Chan K.K., Wong E.S.Y., Wong T.L.I., Cheung L.Y., Wong G.W., Ngan H.Y.S. and Cheung A.N.Y., Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma, *BMC Cancer*. 2019, 19.

Chan K.K.L., Pelvic Exenteration for Advanced Nonrectal Pelvic Malignancy, *Annals of Surgery*. 2019, 270, 899-905.

Guevara A.M., Suarez E., Victoria A., Ngan H.Y.S., Hirschberg A.L., Fedrizzi E., Bautista O., Shields C., Joshi A. and Luxembourg A., Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine, *Hum Vaccin Immunother*, 2019. 15(1), 141-145.

Ip P.C.P., Wang S.Y., Wong G.W., Chow K.L., Lee H.Y.H., Cheung A.N.Y. and Tse K.Y., Napsin A, Hepatocyte Nuclear Factor-1-Beta (HNF-1 $\beta$ ), Estrogen and Progesterone Receptors Expression in Arias-Stella Reaction, *The American*

Kroon H.M., Dudi-Venkata N.N., Bedrikovetski S., Thomas M.L., Kelly M.E., Aalbers A.G.J., Abdul Aziz N., Abraham-Nordling M., Akiyoshi T., Alberda W., Andric M., Antoniou A., Austin K.K., Baker R.P., Bali M., Baseckas G., Bednarski B.K., Beets G.L., Berg P.L., Beynon J., Biondo S., Bordeianou L., Brunner M., Buchwald P., Burger J.W.A., Burling D., Campaign N., Chan K.K.L., Chang G.J., Chew M.H., C Chong P., Christensen H.K., Codd M., Colquhoun A.J., Corr A., Coscia M., Coyne P.E., Creavin B., Damjanovic L., Daniels I.R., Davies M., Davies R.J., de Wilt J.H.W., Denost Q., Dietz D., Dozois E.J., Duff M., Eglinton T., Enriquez-Navascues J.M., Evans M.D., Fearnhead N.S., Frizelle F.A., Garcia-Granero E., Garcia-Sabrido J.L., Gentilini L., George M.L., Glynn R., Golda T., Griffiths B., Harris D.A., Evans M., Hagemans J.A.W., Harji D.P., Heriot A.G., Hohenberger W., Holm T., Jenkins J.T., Kapur S., Kanemitsu Y., Kelley S.R., Keller D.S., Kim H., Koh C.E., Kok N.F.M., Kokelaar R., Kontovounisios C., Kusters M., Larson D.W., Law W.L., Laurberg S., Lee P., Lydrup M.L., Lynch A.C., Mantyh C., Mathis K.L., Martling A., Meijerink W.J.H.J., Merkel S., Mehta A.M., McDermott F.D., McGrath J.S., Mirnezami A., Morton J.R., Mullaney T.G., Mesquita-Neto J.W., Nielsen M.B., Nieuwenhuijzen G.A.P., Nilsson P.J., O'Connell P.R., Palmer G., Patsouras D., Pellino G., Poggioli G., Quinn M., Quyn A., Radwan R.W., Rasheed S., Rasmussen P.C., Regembogen S.E., Rocha R., Rothbarth J., Roxburgh C., Rutten H.J.T., Ryan É., Sagar P.M., Saklani A., Schizas A.M.P., Schwarzkopf E., Scripcariu V., Shaikh I., Shida D., Simpson A., Smart N.J., Smith J.J., Solomon M.J., Sørensen M.M., Steele S.R., Steffens D., Stocchi L., Stylianides N.A., Tekkis P.P., Taylor C., Tsarkov P., Tsukamoto S., Turner W.H., Tuynman J.B., van Ramshorst G.H., van Zoggel D., Vasquez-Jimenez W., Verhoef C., Verstegen M., Wakeman C., Warriar S., Wasmuth H.H., Weiser M.R., Wheeler J.M.D., Wild J., Yip J., Winter D.C. and Sammour T., Palliative pelvic exenteration: A systematic review of patient-centered outcomes, *European Journal of Surgical Oncology*. 2019, 45, 1787-1795.

Leung T.H.Y., Tang W.M., Siu K.Y., Chan D.W., Chan K.K.L., Cheung A.N.Y. and Ngan H.Y.S., CD71(+) population enriched by HPV-E6 protein promotes cancer aggressiveness and radioresistance in cervical cancer cells, *Molecular Cancer Research*. 2019.

Li Z., Zhou W., Zhang Y., Sun W., Yung M.H., Sun J., Li J., Chen C.W., Li Z., Meng Y., Chai J., Zhou Y., Liu S., Cheung A.N.Y., Ngan H.Y.S., Chan D.W., Zheng W.

and Zhu W., ERK regulates HIF-1 $\alpha$ -mediated platinum resistance by directly targeting PHD2 in ovarian cancer, *Clinical Cancer Research*. 2019, 25(19).

Ngan W.L., Tsui M.G., So H.F., Leung W.Y.G., Chan D.W. and Yao K.M., Novel Nuclear Partnering Role of EPS8 With FOXM1 in Regulating Cell Proliferation, *Frontiers in Oncology*. 2019.

Siu K.Y., Jiang Y., Wang J., Han C.Y., Tsang B.K., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades, *Cancers*. 2019, 11(6), 813.

Sun J., Cai X., Yung M.H., Zhou W., Li J., Zhang Y., Li Z., Liu S., Cheung A.N.Y., Ngan H.Y.S., Li Y., Dai Z., Kai Y., Tzatsos A., Peng W., Chan D.W. and Zhu W., miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer, *Oncogene*. 2019, 38, 564-580.

Wang J., Siu K.Y., Jiang Y., Leung T.H.Y., Chan D.W., Cheng R., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1, *OncImmunity*. 2019, 8(11).

Wang M., Perucho J.A.U., Chan Q., Sun J., Ip P.C.P., Tse K.Y. and Lee E.Y.P., Diffusion Kurtosis Imaging in the Assessment of Cervical Carcinoma, *Academic Radiology*. 2019, 27, 94-101.

Wong G.W., Ngan H.Y.S. and Cheung A.N.Y., Placental biology of Down syndrome in relation to increased gene dosage, *Hong Kong Med J*. 2019, 25, 4.

Yu Y., Tse K.Y., Lee H.Y.H., Chow K.L., Tsang H.W., Wong W.C., Cheung E.T.Y., Cheuk W., Lee V.W.K., Chan W.K., Wong A.S.T., Loong H.H.F., Chan K.K.L., Ngan H.Y.S., Cheung A.N.Y. and Ip P.C.P., Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases, *Modern Pathology*. 2019.

## Conference papers

An H., Perucho J.A.U., Chiu W.H.K., Chu M.Y.M. and Tse K.Y., DWI predicts surgical outcome in advanced ovarian cancer, *European Congress of Radiology*.

2019, 10.

- An H., Perucho J.A.U., Chiu W.H.K., Chu M.Y.M., Tse K.Y. and Lee E.Y.P., The impact of tumour burden derived from diffusion-weighted imaging on surgical complexity in primary advanced ovarian cancer, *27th Annual Scientific Meeting of HKCR*. 2019.
- Chan K.K.L., Ngu S.F., Chu M.Y.M., Tse K.Y., Wei N., Liu S., Lau S.K. and Ngan H.Y.S., Primary HPV testing with cytology versus cytology alone in cervical screening, *RCOG World Congress 2019*.
- Ip P.C.P., Lee H.Y.H., Chow K.L., YU Y., Tse K.Y. and Cheung A.N.Y., Evaluation of potential immunotherapy biomarkers in female genital tract malignant melanomas, *The United States and Canadian Academy of Pathology 108<sup>th</sup> Annual Meeting, (2018/2019)*. 2019, 32 (suppl 2), 136.
- Leung R.C.Y., Chan K.T., Liu S. and Ngan H.Y.S., Role of metformin cell proliferation and apoptosis in cervical cancer, *2019 British Gynaecological Cancer Society*. 2019.
- Li J., Ngu S.F., Wei N., Chu M.Y.M., Tse K.Y., Ngan H.Y.S. and Chan K.K.L., The Role of Regular Clinical Examination in the Follow-Up of Gynaecological Oncology Patients – a Randomised Controlled Trial, *British Gynaecological Cancer Society Annual Scientific Meeting, Churchill College, Cambridge*. 2019.
- Ngan H.Y.S. and Ip P.C.P., Comparison of different staging systems for high-grade uterine leiomyosarcoma, *21st International Meeting of the European Society of Gynaecological Oncology*. 2019.
- Ngu S.F., Tse K.Y., Choi K.M.C., Lee E.Y.P., Cheung A.N.Y. and Ngan H.Y.S., Disappearing Uterine Carcinosarcoma Following Uterine Artery Embolisation, *British Gynaecological Cancer Society Annual Scientific Meeting, Churchill College, Cambridge*. 2019.
- Ngu S.F., Chan K.K.L., Tse K.Y., Chu M.Y.M. and Ngan H.Y.S., Uterine Arteriovenous Malformations Following Choriocarcinoma, *XX World Congress on Gestational Trophoblastic Diseases, Toronto, Canada*. 2019.
- Tse K.Y., Leung R.C.Y., Chan K.T., Liu S. and Ngan H.Y.S., Role of metformin cell proliferation and apoptosis in cervical cancer, *British Gynaecological Cancer*

*Society*. 2019.

Wong G.W., Cheung L.Y., Liu S., Ngan H.Y.S. and Cheung A.N.Y., Multiple alterations on genes encoding components of the SWItch/Sucrose Non-Fermentable complex could be found in human papillomavirus-negative cervical cancer, In: Wong OGW, Cheung CLY, Liu SS, Ngan HYS, Cheung AN., *AACR New Horizons in Cancer Research Conference. May 3-5, 2019, Shenzhen, China*. 2019.

Yu Y., Chow K.L., Lee H.Y.H., Cheuk W., Cheung E.T.Y., Chan W.K., Lee V.W.K., Cheung A.N.Y., Tse K.Y. and Ip P.C.P., Evaluation of potential immunotherapy biomarkers in female genital tract malignant melanomas, *108th Annual meeting of The United States and Canadian Academy of Pathology*. Modern Pathology, 2019, 134.

## **Editorship, Invited lectures and keynote speeches**

Chan D.W., Functional characterization of the novel bioactive protein from bitter melon (*Momordica charantia*) in combating ovarian cancer oncogenesis and chemoresistance, *the Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology*, May 17-18, 2019.

Chan D.W. and Ngan H.Y.S., The miR-141/Hippo is a novel signaling axis in tumour-stromal crosstalk network promoting ovarian cancer metastatic colonization, *The 3rd Meeting of International Society of Precision Cancer Medicine (ISPCM 2019)*, in *Novotel Ambassador Seoul Dong daemundaemun, Seoul, Republic of Korea*. 2019.

Chan K.K.L., Cervical Cancer Prevention in Hong Kong, *CICAMS-IARC “China ASEAN Cancer Prevention and Control Program 2019*.

Chan K.K.L., Cervical cancer in the era of HPV, *26th Asia and Oceania Federation of Obstetrics and Gynecology (AOFOG) congress, Philippines*. 2019.

Chan K.K.L., Council Meeting of Chinese Medical Doctor Association (CMDA), 中國醫師協會, *Chinese Medical Doctor Association, China, 30-31 August*. 2019.

Chan K.K.L., Expert Input Forum for HPV Vaccines 2019, *MSD Asia Pacific*,

*Singapore, 16-17 February. 2019.*

Chan K.K.L., 宫颈癌预防进展, *HKU SZH Gyn Onc Symposium*. 《第二届港大医院妇科肿瘤高峰论坛》, 2019.

Chan K.K.L., HPV testing in primary cervical screening in a well screened Chinese population, *AOGIN 2019 Beijing*. 2019.

Chan K.K.L., Is Hormonal Treatment still an option on ovarian cancer, *The 1st International Congress of Cancer and Clinical Oncology, Singapore*. 2019.

Chan K.K.L., Quality assurance on postgraduate training, 毕业后培训质量保证, *2019 The Second Greater Bay Area Postgraduate Medical Education Forum*. 《2019年第二届粤港澳大湾区毕业后医学教育论坛》, 2019.

Chan K.K.L., SGO 50th Annual Meeting on Women's Cancer, *Hawaii Convention Center, Honolulu, 15-19 March*. 2019.

Chan K.K.L., Salvage Surgery for recurrent cervical cancers after primary radiotherapy, *Gleneagles Hospital CME Talk*. 2019.

Ngan H.Y.S., 2018 FIGO Cervical Cancer Staging System and Updates in guidelines, *The Red House Form & The 5th International Obstetrics & Gynecology Summit, Shanghai, China, June 15*. 2019.

Ngan H.Y.S., Cervical Cancer Staging, *第五届华夏医学妇产科论坛, Wuhan, PRC, March 28 to 31*. 2019.

Ngan H.Y.S., Endometrial hyperplasia: classification and treatment options, *National Gynaecology Conference, Kuala Lumpur, Malaysia, October 5-6*. 2019.

Ngan H.Y.S., HPV Vaccine in Hong Kong, *The Obstetrical and Gynaecological Society of Hong Kong, Hong Kong, June 1*. 2019.

Ngan H.Y.S., HPV test as screening tool – primary vs co-testing, *The 5th Conference of Chinese Society for Colposcopy and Cervical Pathology (CSCCP), Shenzhen, China, May 11*. 2019.

Ngan H.Y.S., Hormonal therapy for early endometrial cancers, *National Gynaecology Conference, Kuala Lumpur, Malaysia, October 5-6*. 2019.



*oncology Conference, Kuala Lumpur, Malaysia, October 5-6, 2019.*

Ngan H.Y.S., Laparoscopic vs laparotomy in cervical cancer treatment, *22nd Chinese Society of Clinical Oncology (CSCO), September 18-22, 2019 Xiamen, China.* 2019.

Ngan H.Y.S., Optimising treatment of metastatic ovarian cancer and cervical cancer with avastin: an experience sharing from Hong Kong”, *Lunch symposium sponsored by Roche Malaysia, Kuala Lumpur, Malaysia, October 4.* 2019.

Ngan H.Y.S., Persistence – Risk Scoring - Staging, *The XX Biannual World Congress on Gestational Trophoblastic Diseases (ISSTD), Toronto, Canada, October 20-23.* 2019.

Ngan H.Y.S., Translating basic research to clinical practice, *26th Asia and Oceania Federation of Obstetrics & Gynaecology (AFOG) Congress, Manila, Philippines, November 10-14.* 2019.

Ngan H.Y.S., Treatment of Cervical Cancer, 106. *The Asia Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) conference and the 17th Annual Meeting of National Cervical Cancer Consortium (17th NCCC), Beijing, China, April 24-28.* 2019.

Ngan H.Y.S., Treatment of Endometrial Cancer, *The 7th Regional Conference of the European Society of Gynaecological Endoscopy and the 22th Gynecology Oncology and Minimally invasive surgery - New Advances Symposium, Guangzhou, China, May 23-26.* 2019.

Ngan H.Y.S., Updates on cervical cancer prevention, 2019 *国际整合妇科罗湖论坛; 女性生殖道发育异常及盆底功能障碍性疾病 诊治新进展省级继教班, Shenzhen, China, December 27-29.* 2019.

Ngan H.Y.S., 产科危急重症救治相关问题, 2019 *年产科危急重症救治进展学习班, Foshan, PRC, March 23.* 2019.

Ngan H.Y.S., 婦科醫生的專科培訓 , 2019 *年廣東省醫學會婦產科學學術年會, Guangzhou, July 12-14.* 2019.

Ngan H.Y.S., 導師對住培醫師階段性工作的評估與反饋, 2019 *年住院醫師規範*

化培訓北京高峰論壇, Beijing, China, August 31. 2019.

Ngu S.F., Interesting case presentation, *The 2nd Gynaecological Oncology Symposium, The University of Hong Kong-Shenzhen Hospital*. 2019.

Ngu S.F., One year after the LACC (Laparoscopic Approach to Cervical Cancer) trial, what should we do now?, *The Hong Kong College of Obstetricians and Gynaecologists Postgraduate Seminar, Hong Kong*. 2019.

Ngu S.F., Understanding The Common Adverse Events Of Parp Inhibitors And Their Management, *Ovarian Cancer Maintenance Therapy Masterclass*. 2019.

Tse K.Y., Advance in the use of PARPi in ovarian cancer after the SGO, SGO PARPi 卵巢癌最新进展, 《2019 南昌大學贛鄱婦產科高峰論壇》, 2019.

Tse K.Y., COVID-19 and Gynaecological Cancer Management: Chemotherapy, Targeted Therapy, and Immunotherapy, *Asia & Oceania Federation of Obstetrics & Gynaecology (AFOG) Webinar*.

Tse K.Y., Guest Editor, *Frontiers in Oncology*.

Tse K.Y., Immunotherapy in gynecological cancer, *The HKU-Shenzhen Hospital 2nd Gynaecological Oncology Symposium*. 2019.

Tse K.Y., Set-up: its importance cannot be underestimated, *Asian Society for Gynecological Robotic Surgery 2019*.

Tse K.Y., The use of PARPi in primary advanced ovarian cancer, *寧波市醫學會婦產科分會年會*. 2019.

## **Prizes and awards**

Ngan H.Y.S., "Best Volunteer Award" in recognition of voluntary contribution to the Family Planning Association of Hong Kong and to International Planned Parenthood Federation as a member of International Medical Advisory Panel, *International Planned Parenthood Federation*. 2019.

